CONFIDENTIAL DEEPTECH PLATFORM

Next-Generation In Silico Cardiac Safety & Arrhythmia Risk Profiling

Proprietary biophysical and computational framework compliant with FDA CiPA and OECD guidelines. Operating in stealth mode pending patent finalization and strategic licensing partnerships.

100% Concordance
FDA CiPA 12-Drug Benchmark Panel
OECD Principles 1–5
Audit-Ready QMRF Regulatory Format
Zero Cloud Egress
100% Air-Gapped & IP Isolated
Swiss DeepTech Asset
Available for Strategic IP Licensing

Confidential De-risking Architecture for Life Sciences

HeartSim AI addresses the multi-billion-dollar false-positive attrition trap in safety pharmacology without disclosing internal proprietary computational mechanics prior to patent closure.

Zero False-Positive Elimination

Overcomes the legacy hERG single-channel bottleneck by modeling multi-channel electrophysiological balance, eliminating false candidate attrition.

Regulatory Alignment (CiPA & OECD)

Directly mapped to FDA Comprehensive In Vitro Proarrhythmia Assay (CiPA) endpoints (qNet in µC/µF) and OECD Principles 1-5 for model validation.

100% Air-Gapped Confidentiality

Shipped as an isolated on-premises runtime. Zero telemetry, zero cloud egress. Proprietary compounds and chemical structures never leave client perimeter.

Strategic IP Acquisition & Licensing

Engineered as an institutional IP asset available for exclusive enterprise licensing, full patent transfer, or co-development with pharmaceutical leaders.

100% Blind Concordance on FDA CiPA Reference Drugs

Validated across the complete FDA CiPA 12-drug panel (Dofetilide, Quinidine, Bepridil, Sotalol, Cisapride, Terfenadine, Ondansetron, Astemizole, Verapamil, Ranolazine, Mexiletine, Diltiazem) with zero clinical false positives.

Bilateral Blind Challenge Protocol

We invite qualified pharma discovery partners to challenge the HeartSim AI runtime using blinded proprietary internal chemical series under bilateral Swiss NDA.

Apply for Blind Challenge

Licensing Models & IP Acquisition

Structured for flexible engagement with global pharmaceutical sponsors, emerging biotech ventures, and strategic acquirers.

Global Pharma

Enterprise On-Premises License

Air-gapped deployment across corporate discovery pipelines for pre-synthesis high-throughput library triage.

Inquire Under NDA
Strategic Asset
Strategic Acquirers

Full Intellectual Property Acquisition

Complete transfer of proprietary source architecture, mathematical frameworks, and pre-trained models for in-house monopoly.

Inquire Under NDA
Preclinical CROs

Commercial Service Integration

White-label in silico cardiosafety reporting package to augment high-throughput patch-clamp and telemetry services.

Inquire Under NDA

Request Executive Dossier & Bilateral NDA

Due to ongoing patent filings and trade secret protection, full technical documentation and benchmark logs are shared strictly under bilateral Swiss Non-Disclosure Agreements.

HeartSim AI AG — Headquarters Canton of Ticino, Switzerland (Swiss Life Sciences Cluster)

Request Executive Dossier & Bilateral NDA

Due to ongoing patent filings and trade secret protection, full technical documentation and benchmark logs are shared strictly under bilateral Swiss Non-Disclosure Agreements.